[Congressional Record Volume 160, Number 146 (Wednesday, December 3, 2014)]
[House]
[Page H8344]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]




                              {time}  1800
      ADDING EBOLA TO THE FDA PRIORITY REVIEW VOUCHER PROGRAM ACT

  Mr. BILIRAKIS. Mr. Speaker, I ask unanimous consent to take from the 
Speaker's table the bill (S. 2917) to expand the program of priority 
review to encourage treatments for tropical diseases, and ask for its 
immediate consideration in the House.
  The Clerk read the title of the bill.
  The SPEAKER pro tempore. Is there objection to the request of the 
gentleman from Florida?
  There was no objection.
  The text of the bill is as follows:

                                S. 2917

       Be it enacted by the Senate and House of Representatives of 
     the United States of America in Congress assembled,

     SECTION 1. SHORT TITLE.

       This Act may be cited as the ``Adding Ebola to the FDA 
     Priority Review Voucher Program Act''.

     SEC. 2. PRIORITY REVIEW TO ENCOURAGE TREATMENTS FOR TROPICAL 
                   DISEASES.

       Section 524 of the Federal Food, Drug, and Cosmetic Act (21 
     U.S.C. 360n) is amended--
       (1) in subsection (a)(3)--
       (A) by redesignating subparagraph (Q) as subparagraph (R);
       (B) by inserting after subparagraph (P) the following:
       ``(Q) Filoviruses.''; and
       (C) in subparagraph (R), as so redesignated, by striking 
     ``regulation by'' and inserting ``order of''; and
       (2) in subsection (b)--
       (A) in paragraph (2), by adding ``There is no limit on the 
     number of times a priority review voucher may be transferred 
     before such voucher is used.'' after the period at the end; 
     and
       (B) in paragraph (4), by striking ``365 days'' and 
     inserting ``90 days''.

  The bill was ordered to be read a third time, was read the third 
time, and passed, and a motion to reconsider was laid on the table.

                          ____________________